NERV has been granted a new patent
Jan 15, 2025, 11:35 PM
-4.20%
What does NERV do
Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for central nervous system diseases, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Founded in 2014, it employs 9 people and co-developed seltorexant for insomnia and major depressive disorder.
NERV filed a patent for "gastro-resistant controlled release oral dosage forms" on Mon, June 10, 2024. The patent was officially published on Thu, January 9, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.